Myriad Genetics stock hits 52-week low at $12.16 amid market challenges
Myriad Genetics , Inc. (NASDAQ:MYGN) stock has reached a new 52-week low, touching down at $12.16, as the company faces a challenging market environment. According to InvestingPro data, technical ...
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance
As set forth above, the company’s financial results for the quarter and full year ended December 31, 2024 set forth in this press release are preliminary and subject to Myriad Genetics’ normal quarter ...
Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report
SALT LAKE CITY, Jan. 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today ...